• Explore /
  • Poster
  • / A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).

A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).

Abstract Video & Slides Poster

Authors

Hidetoshi Hayashi

Hidetoshi Hayashi

Kindai University Faculty of Medicine, Osaka, Japan

Hidetoshi Hayashi , Shunichi Sugawara , Yasushi Fukuda , Yuki Sato , Satoru Miura , Keiichi Ota , Yuichi Ozawa , Satoshi Hara , Junko Tanizaki , Koichi Azuma , Shota Omori , Motoko Tachihara , Kazumi Nishino , Shinobu Hosokawa , Yasutaka Chiba , Koji Haratani , Kazuko Sakai , Kazuto Nishio , Nobuyuki Yamamoto , Kazuhiko Nakagawa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

jRCTs051180133

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9037)

DOI

10.1200/JCO.2021.39.15_suppl.9037

Abstract #

9037

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Aaron Elliott Lisberg

First Author: David Paul Carbone

First Author: Panpan Zhang

First Author: Melissa Lynne Johnson